OncoMatch/Clinical Trials/NCT06908070
Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab
Is NCT06908070 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Consolidation durvalumab for non-small cell lung cancer stage iii.
Treatment: Consolidation durvalumab — Lung cancer presents a significant treatment challenge, particularly in the heterogeneous stage III NSCLC patient population. While chemotherapy combined with high-dose radiotherapy (60 Gy in 30 fractions of 2 Gy once daily) is currently the recommended approach for unresectable stage III cases, it is associated with significant rates of locoregional and distant failures. Notably, the introduction of durvalumab consolidation therapy after chemoradiotherapy (CRT), as demonstrated in the PACIFIC study, has shown improved overall survival, primarily attributed to enhanced distant control. This improvement prompts further interest in investigating whether further improvements in locoregional control can lead to improved survival for patients. The present study aims to evaluate the feasibility of post-CRT surgery in patients with initially considered unresectable stage III (non-N3) NSCLC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage III (TNM 8th edition)
Excluded: Stage TXN3
stage III (non-N3) NSCLC (TNM 8th edition), before start of concurrent chemoradiotherapy (CRT)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1 therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.
Cannot have received: chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies
Exception: last dose ≤4 weeks prior to the first dose of study drug
Receipt of the last dose of anticancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies) ≤4 weeks prior to the first dose of study drug.
Lab requirements
Blood counts
adequate normal organ and marrow function, as deemed acceptable by the treating physician in the context of CRT
Kidney function
adequate normal organ and marrow function, as deemed acceptable by the treating physician in the context of CRT
Liver function
adequate normal organ and marrow function, as deemed acceptable by the treating physician in the context of CRT
Demonstrate adequate normal organ and marrow function, as deemed acceptable by the treating physician in the context of CRT.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify